Breaking News Instant updates and real-time market news.

APYX

Apyx Medical

$7.23

0.25 (3.58%)

16:28
11/11/19
11/11
16:28
11/11/19
16:28

Apyx Medical reports Q3 EPS (13c), consensus (18c)

Reports Q3 revenue $7.6M, consensus $6.78M. "Our performance during the third quarter was impressive and represents a continuation of the better-than-expected growth and profitability performance we have generated throughout 2019," said Charlie Goodwin, President and Chief Executive Officer. "I am extremely proud of the organization's ability to execute our strategic growth objectives and the progress we made during the third quarter is notable: we drove revenue growth of 106% year-over-year, led by 104% growth in Advanced Energy sales, we made advancements in both our clinical and regulatory strategies, and we realized early benefits to our Advanced Energy gross margins as a result of our focus on improving our manufacturing efficiency."

  • 11

    Nov

  • 12

    Nov

APYX Apyx Medical
$7.23

0.25 (3.58%)

03/14/19
PIPR
03/14/19
NO CHANGE
Target $10
PIPR
Overweight
Apyx Medical posted another solid quarter, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Apyx Medical posted another solid quarter in-line with its preannouncement, highlighted by "strong advanced energy growth off a tough comp." While the company's expense guidance may make the earnings outlook a little less favorable in the near-term, given the light penetration into this $1.5B market and the potential for several international expansions in 2019, its growth "should remain healthy for many years," O'Brien tells investors in a research note. He encourages risk tolerant investors to own the name and reiterates an Overweight rating on Apyx Medical with a $10 price target.
04/02/19
PIPR
04/02/19
NO CHANGE
Target $10
PIPR
Overweight
Piper continues to believe Apyx Medical will receive 510k clearance
Apyx Medical's decision to withdraw its 510k submission for dermal resurfacing following FDA pushback on various aspects of their study removes a source of upside and will "no doubt give legs to some of the theories floated in the short report," Piper Jaffray analyst Matt O'Brien tells investors in a research note. However, the analyst continues to believe that once Apyx "irons out" some of its clinical hurdles, the company will receive this clearance. Additionally, O'Brien feels that the product's use off-label for these procedures is likely reflective of J-Plasma's "unique utility in these situations," which allows him to remain constructive on the stock. He reiterates an Overweight rating on Apyx Medical with a $10 price target.
04/02/19
JMPS
04/02/19
NO CHANGE
Target $8
JMPS
Outperform
Apyx Medical price target lowered to $8 from $12 at JMP Securities
JMP Securities analyst David Turkaly lowered his price target on Apyx Medical shares to $8 from $12 after the company said it will voluntarily withdraw its 510(k) application for the use of its Renuvion product in dermal resurfacing procedures. Despite his belief that negative investor sentiment could be priced into the stock in the near-term, Turkaly said Apyx is still a significant grower and he still expects over 50% revenue growth in both 2019 and 2020, leading him to keep an Outperform rating on the shares.
05/08/19
PIPR
05/08/19
NO CHANGE
Target $7
PIPR
Overweight
Apyx Medical price target lowered to $7 from $10 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target on Apyx Medical to $7 after its Q1 results, adjusting his model after the company indicated that its pursuit of a dermal resurfacing indication with the FDA would be outside of the 2019 timeline. The analyst keeps his Overweight rating however and expects Apyx Medical's growth to remain healthy thanks to its "international expansion and core utilization in the US."

TODAY'S FREE FLY STORIES

PRSC

Providence Service

$57.58

-0.39 (-0.67%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Hot Stocks
LogistiCare to provide NEMT brokerage services to certain CCO members »

PacificSource Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$298.02

8.67 (3.00%)

13:06
12/05/19
12/05
13:06
12/05/19
13:06
Recommendations
Biogen analyst commentary  »

Stifel still sees lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$62.50

-86.72 (-58.12%)

12:55
12/05/19
12/05
12:55
12/05/19
12:55
Downgrade
Sage Therapeutics rating change  »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$181.49

-2.79 (-1.51%)

12:55
12/05/19
12/05
12:55
12/05/19
12:55
Options
Constellation Brands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

12:55
12/05/19
12/05
12:55
12/05/19
12:55
General news
Atlanta Fed's Q4 GDP Nowcast now projects a 1.48% growth rate »

Atlanta Fed's Q4 GDP…

BIG

Big Lots

$18.89

-1.03 (-5.17%)

, GCO

Genesco

$37.08

0.52 (1.42%)

12:51
12/05/19
12/05
12:51
12/05/19
12:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BIG

Big Lots

$18.89

-1.03 (-5.17%)

GCO

Genesco

$37.08

0.52 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

CLDR

Cloudera

$9.86

(0.00%)

, OKTA

Okta

$120.39

-1.43 (-1.17%)

12:51
12/05/19
12/05
12:51
12/05/19
12:51
Earnings
Notable companies reporting after market close »

Notable companies…

CLDR

Cloudera

$9.86

(0.00%)

OKTA

Okta

$120.39

-1.43 (-1.17%)

ULTA

Ulta Beauty

$237.92

-1.44 (-0.60%)

DOCU

DocuSign

$69.41

-0.565 (-0.81%)

ZM

Zoom Video

$70.00

0.05 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 16

    Dec

ARQL

ArQule

$9.59

0.275 (2.95%)

12:45
12/05/19
12/05
12:45
12/05/19
12:45
Options
ArQule call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

MMM

3M

$163.96

-3.145 (-1.88%)

12:32
12/05/19
12/05
12:32
12/05/19
12:32
Hot Stocks
Breaking Hot Stocks news story on 3M »

3M shares down 2% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MMM

3M

$163.96

-3.145 (-1.88%)

12:31
12/05/19
12/05
12:31
12/05/19
12:31
Hot Stocks
3M CFO says Q4 'looks a lot like Q3,' some 'hopefulness' around end markets »

CFO Michael Roman says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AXTA

Axalta Coating

$30.13

0.54 (1.82%)

12:25
12/05/19
12/05
12:25
12/05/19
12:25
Options
Axalta Coating call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$35.30

0.25 (0.71%)

, TSLA

Tesla

$330.39

-2.78 (-0.83%)

12:25
12/05/19
12/05
12:25
12/05/19
12:25
Periodicals
GM CEO sees big opportunity in all-electric pickup trucks, CNBC reports »

General Motors (GM) CEO…

GM

General Motors

$35.30

0.25 (0.71%)

TSLA

Tesla

$330.39

-2.78 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Jan

HOV

Hovnanian

$24.73

3.39 (15.89%)

12:23
12/05/19
12/05
12:23
12/05/19
12:23
Earnings
Hovnanian surges 15% after Q4 report, revenue and deliveries climb »

Shares of home-builder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/05/19
12/05
12:17
12/05/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/05/19
12/05
12:16
12/05/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$55.72

-0.05 (-0.09%)

12:15
12/05/19
12/05
12:15
12/05/19
12:15
Options
Southwest put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

  • 23

    Jan

SIGA

Siga Technologies

$4.39

-0.01 (-0.23%)

12:13
12/05/19
12/05
12:13
12/05/19
12:13
Hot Stocks
Siga announces CDND intent to purchase up to 15,325 courses of oral TPOXX »

SIGA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$20.06

0.04 (0.20%)

12:11
12/05/19
12/05
12:11
12/05/19
12:11
Conference/Events
Oportun Financial management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

GALT

Galectin Therapeutics

$2.98

-0.06 (-1.97%)

12:09
12/05/19
12/05
12:09
12/05/19
12:09
Hot Stocks
Galectin Therapeutics plans adaptively designed Phase 3 NASH-RX trial »

Galectin Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$348.04

-0.85 (-0.24%)

12:09
12/05/19
12/05
12:09
12/05/19
12:09
Periodicals
Boeing to SEC: Doesn't see 737 MAX cancellations impacting revenue, Reuters says »

In a letter to the SEC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MASI

Masimo

$156.34

-1.11 (-0.70%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Conference/Events
Masimo management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

ACHN

Achillion

$6.16

-0.025 (-0.40%)

12:05
12/05/19
12/05
12:05
12/05/19
12:05
Options
Achillion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 19

    Dec

TVTY

Tivity Health

$22.60

-0.23 (-1.01%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Tivity Health management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MIC

Macquarie Infrastructure

$42.49

0.43 (1.02%)

12:04
12/05/19
12/05
12:04
12/05/19
12:04
Conference/Events
Macquarie Infrastructure management to meet with Suntrust »

Group Dinner with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$38.57

0.09 (0.23%)

12:03
12/05/19
12/05
12:03
12/05/19
12:03
Conference/Events
TriCo Bancshares management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.